Pharma Companies Collaborate to Collate Capital Project Benchmarking Costs
Lead company is seeking others to join the initiative.
Consultancy firm Linesight (London, UK) reports that it is leading a collaboration with major pharmaceutical companies on benchmarking data.
Merck, AstraZeneca, BMS, Pfizer, GSK, Ipsen, Viatris, Wuxi and others are participating in a global effort to collate capital project benchmarking costs, schedule intelligence and analysis in a central, independent, confidential fashion. Linesight reports that it is now seeking others to join this initiative.
“The more project data we collate, the more valuable it will be to the industry at large, which is why we are seeking further companies to get involved. This is a hugely significant initiative, and one which will have global impact for many years to come,” commented Nigel Barnes, Director of Life Sciences EMEA, Linesight.
Steve White, Leader of Global Estimating and Control at Merck, said, “Benchmarking data is essential to gauge the capital effectiveness of our projects both internally and externally with other pharmaceutical companies.”
Steve Townsend, Director Project Controls, Global Capital Projects, GSK added, “As we seek to continuously improve our project scoping and delivery, we must understand how we compare to our peers within the industry. Participating in this program offers us the necessary access to key, comparative data and should provide us with improved confidence.”
For further information on the program, contact lifesciences@linesight.com
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
